Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Stuttgart - Delayed Quote EUR

BeiGene, Ltd. (49B.SG)

Compare
15.76
+0.32
+(2.04%)
As of 10:04:42 AM GMT+2. Market Open.
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
3,810,241
3,810,241
2,458,779
1,415,921
1,176,283
Cost of Revenue
594,089
594,089
379,920
286,475
164,906
Gross Profit
3,216,152
3,216,152
2,078,859
1,129,446
1,011,377
Operating Expense
3,784,351
3,784,351
3,286,595
2,919,111
2,450,112
Operating Income
-568,199
-568,199
-1,207,736
-1,789,665
-1,438,735
Net Non Operating Interest Income Expense
47,836
47,836
74,009
52,480
-15,757
Other Income Expense
-12,638
-12,638
307,891
-223,852
15,904
Pretax Income
-533,001
-533,001
-825,836
-1,961,037
-1,438,588
Tax Provision
111,785
111,785
55,872
42,778
19,228
Net Income Common Stockholders
-644,786
-644,786
-881,708
-2,003,815
-1,457,816
Diluted NI Available to Com Stockholders
-644,786
-644,786
-881,708
-2,003,815
-1,457,816
Basic EPS
-0.63
-0.47
-0.65
-1.49
-1.17
Diluted EPS
-0.63
-0.47
-0.65
-1.49
-1.17
Basic Average Shares
1,359,152.77
1,368,746.79
1,357,034.55
1,340,729.57
1,206,210.05
Diluted Average Shares
1,359,152.77
1,368,746.79
1,357,034.55
1,340,729.57
1,206,210.05
Total Operating Income as Reported
-568,199
-568,199
-1,207,736
-1,789,665
-1,438,735
Total Expenses
4,378,440
4,378,440
3,666,515
3,205,586
2,615,018
Net Income from Continuing & Discontinued Operation
-644,786
-644,786
-881,708
-2,003,815
-1,457,816
Normalized Income
-644,786
-644,786
-881,708
-2,003,815
-1,457,816
Interest Income
47,836
47,836
74,009
52,480
--
Net Interest Income
47,836
47,836
74,009
52,480
-15,757
EBIT
-568,199
-568,199
-1,207,736
-1,789,665
-1,438,735
EBITDA
-396,437
-396,437
-1,120,061
-1,723,387
-1,392,278
Reconciled Cost of Revenue
594,089
594,089
379,920
286,475
119,199
Reconciled Depreciation
171,762
171,762
87,675
66,278
46,457
Net Income from Continuing Operation Net Minority Interest
-644,786
-644,786
-881,708
-2,003,815
-1,457,816
Normalized EBITDA
-396,437
-396,437
-1,120,061
-1,723,387
-1,392,278
Tax Rate for Calcs
0
0
0
0
0
12/31/2021 - 8/8/2018

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

688266.SS Suzhou Zelgen Biopharmaceuticals Co.,Ltd.
105.67
+1.77%
 
CLCS Cell Source, Inc.
0.3000
+15.38%
 
1548.HK GENSCRIPT BIO
10.420
+3.78%
 
ACLX Arcellx, Inc.
59.12
+4.33%
 
MRUS Merus N.V.
41.57
+7.64%
 
ELEV Elevation Oncology, Inc.
0.2643
-2.11%
 
LEGN Legend Biotech Corporation
32.32
+3.33%
 
IMVT Immunovant, Inc.
14.75
-0.27%
 
UCB.BR UCB SA
133.50
-0.85%
 
RPRX Royalty Pharma plc
31.87
+2.11%